Everolimus [EVE1]

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy

  1. I confirm that this application is being made by and the first cycle of systemic anti-cancer therapy of everolimus with exemestane will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
  2. I confirm that the patient has ER +ve, HER2 –ve metastatic breast cancer
  3. I confirm that the patient has no symptomatic visceral disease
  4. I confirm that everolimus will be given in combination with exemestane
  5. I confirm that the patient has had previous treatment with a non-steroidal aromatase inhibitor
  6. I confirm that the patient has had no previous treatment with exemestane for metastatic breast cancer
  7. I confirm the patient has received no more than one line of cytotoxic chemotherapy for the treatment of advanced breast cancer.
  8. I confirm the licensed dose and frequency of everolimus will be used.

[NHS funded]{.badge .rounded-pill .bg-success} From: 21 December 2016

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA421 (21 December 2016)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.